Mazi Alimohamed's questions to Amarin Corporation PLC (AMRN) leadership • Q1 2025
Question
Mazi Alimohamed of Leerink Partners asked about Amarin's plans for generating additional real-world evidence or clinical data to expand VASCEPA's labeling or strengthen its differentiation against generics and emerging lipid management therapies.
Answer
President and CEO Aaron Berg and executive Steven Ketchum responded. Berg stated that Amarin is continuously generating new data to differentiate the product, highlighting its unique ability to address residual cardiovascular risk. Ketchum added that the company continues to mine the rich REDUCE-IT dataset, present findings at major medical congresses on mechanisms of action, and support external collaborations to reinforce the drug's scientific foundation.